1. Cutrell A, Hernandez J, Brothers C et al. 2008 Is abacavir (ABC)-containing combination antiretroviral therapy (CART) associated with myocardial infarction (MI)? No association identified in pooled summary of 54 clinical trials A Cutrell, J Hernandez, C Brothers, J Yeo, W Burkle, W Spreen. XVII International AIDS Conference, 3-8 August 2008, Mexico City

2. Cutrell A, Hernandez J, Brothers C et al. 2008 Background and Objective The D:A:D study group recently reported an unexpected increase in risk of MI with ABC and ddI in a large, prospective observational cohort (Lancet 2008; 371:1417-26). To determine whether there is an increase in cardiovascular events associated with ABC containing CART as compared to non-ABC containing CART using GSK-sponsored clinical trials contained in the GSK HIV Data Repository.

3. Cutrell A, Hernandez J, Brothers C et al. 2008 Methods (1) GSK HIV Data Repository – history/purpose GSK-sponsored clinical trials with > 24 weeks of follow up with data from 1995-2006 were analyzed. –Data from 54 clinical trials analyzed: 13/54 adult trials were randomized for ABC vs control 33/54 trials included ABC in background ART 8/54 trials did not include ABC Includes data from 14683 subjects (14174 adults and 509 children) Descriptive statistics were summarized for naïve and experienced subjects treated with and without ABC.

4. Cutrell A, Hernandez J, Brothers C et al. 2008 Methods (2) To capture events of interest (myocardial ischemia or infarction) all data were queried for events coded as “ Coronary Artery Disorders ” and “ Ischemic Coronary Artery Disorders ” using MeDRA –Specific preferred terms included: coronary artery atherosclerosis, coronary artery disease, coronary artery occlusion, acute MI, angina pectoris, angina unstable, MI and myocardial ischemia.

5. Cutrell A, Hernandez J, Brothers C et al. 2008 Methods (3) All fatal cases (any cause) in the HIV Data Repository were reviewed by an external cardiologist. Framingham risk not calculated at baseline – not all factors routinely collected –Smoking, hypertension, HDL levels Rates per 1000 person/years were calculated, and Poisson regression models were used to calculate unadjusted relative rates and 95% confidence intervals using SAS.

6. Cutrell A, Hernandez J, Brothers C et al. 2008 Demographic and HIV-disease Characteristics at Baseline ADULT NAIVEADULT EXPERIENCED ABC N=5859 No ABC N=2406 ABC N=3643 No ABC N=2266 Age at Screening, n Median, year (min-max) 5859 36 (17-78) 2406 35 (18-74) 3639 40 (18-78) 2263 39 (18-74) Race, n White Black 5728 49% 29% 2314 54% 22% 3591 64% 21% 2265 73% 16% Sex, n Male 5858 78% 2406 79% 3643 86% 2266 85% Viral Load (log 10 ), n Median (Min-Max) 5793 4.81 (1.28- 7.64) 2397 4.67 (1.28-6.6) 3626 4.25 (0.84-6.74) 2247 4.18 (1.38-7.05) CD4 Count, n Median (Min-Max) 5819 273 (0-1883) 2393 337 (0-1729) 3629 265 (0-2089) 2250 295 (0-1799)

7. Cutrell A, Hernandez J, Brothers C et al. 2008 Baseline Lipids and Glucose (mmol/L) n Median (Min-Max) ADULT NAIVEADULT EXPERIENCED ABC N=5859 No ABC N=2406 ABC N=3643 No ABC N=2266 Cholesterol 5484 4.1 (1.0-10.1) 2272 4.2 (1.6-10.1) 2249 4.8 (0.05-15.0) 1808 4.6 (1.8-15.0) LDL 2143 2.5 (0.1-6.3) 166 2.7 (0.8-6.4) 39 3.2 (1.0-5.5) 23 3.7 (1.3-5.2) HDL 2215 0.9 (0.05-3.1) 172 0.9 (0.2-2.5) 48 1.0 (0.3-2.6) 24 1.1 (0.5-1.5) Triglycerides 5482 1.4 (0.3-28.9) 2272 1.4 (0.2-15.4) 2234 2.1 (0.04-38.1) 1803 1.9 (0.4-35.3) Glucose4999 5.0 (1.3-27.2) 2353 5.0 (0.9-24.1) 2201 5.2 (2.2-26.0) 1662 5.2 (2.1-26.2)

8. Cutrell A, Hernandez J, Brothers C et al. 2008 CV Outcomes - Exposure to ABC Compared with No Exposure to ABC Exposure to ABC Events /Patients FrequencyEvents /Person- Years Rate /1000 Person- Years Relative rate (95% CI) Any Myocardial Infarction or Acute Myocardial Infarction: None 7/50440.139%11/46532.36 ABC CART11/96390.114%16/78452.040.863 (0.40,1.86) Any ischemic Coronary Artery Disease or Disorder: None 21/50440.416%27/46425.82 ABC CART24/96390.249%27/78323.450.593 (0.35,1.01)

9. Cutrell A, Hernandez J, Brothers C et al. 2008 CV Outcomes - Exposure to ABC or No ABC (12 Adult Randomized Trials) Exposure to ABC Events /Patients FrequencyEvents /Person- Years Rate /1000 Person- Years Relative rate (95% CI) Any Myocardial Infarction or Acute Myocardial Infarction: None 6/16920.355%7/17064.10 ABC CART2/15700.127%4/18632.150.523 (0.15 – 1.79) Any ischemic Coronary Artery Disease or Disorder: None 13/16920.768%13/17027.64 ABC CART5/15700.318%8/18604.300.563 (0.23-1.36)

10. Cutrell A, Hernandez J, Brothers C et al. 2008 Strengths and Limitations Prospective clinical trial data with large number of patients exposed to ABC, consistent data collection Standard and real-time monitoring and follow up of all reported AEs External expert review supportive Post-hoc analysis Duration of exposure on average 24-48 weeks Studies not designed to detect CV risk specifically Low event rate therefore less power

11. Cutrell A, Hernandez J, Brothers C et al. 2008 Conclusion Overall, among pts in the GSK HIV Data Repository: –the incidence rate of MI and Coronary Artery Disorders was low –there was no difference in incidence of ischemic coronary artery events or myocardial infarction in subjects who received abacavir-containing vs. non- ABC containing CART Further study is needed to fully evaluate the association of ABC and cardiovascular disease.

12. Cutrell A, Hernandez J, Brothers C et al. 2008 What’s Next to Further Address the Question? Analysis of Internal Clinical Trial Data Continued vigilance of spontaneous event data and published literature  In all future studies, incorporate cardiovascular risk factor and biomarker collection  Mechanism research  Additional cohort collaborations  Analyze inflammatory markers in current and future studies

13. Cutrell A, Hernandez J, Brothers C et al. 2008 HEAT Biomarker Analysis: Geometric Mean (95% CI) by Study Week (ITT-E) n (obs) Epzicom =243248230256251232 Truvada =249 235216252 236216 Interleukin 6 (IL-6) High Sensitivity C-Reactive Protein (hsCRP) Poster LBPE1138 Thursday August 7, 2008

14. Cutrell A, Hernandez J, Brothers C et al. 2008 Acknowledgments The authors wish to thank… Harry Staines, Suki Pabla, Dupe Bassey, Lee Tombs and Pinal Patel at SRG Interesource Satellite Operations for statistical support Drs. Peter Kowey & Gary Koch for expert input Investigators who supported the clinical trials All of the patient volunteers.